Shield Therapeutics (GB:STX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shield Therapeutics reports significant growth in Q3 2024, with ACCRUFeR® net revenues reaching $7.2 million, a notable increase driven by prescription demand in the US. The company is strengthening its financial position by expanding accounts receivable financing to $15 million and implementing a 10% cost-saving plan. Additionally, Shield is in discussions with AOP Health for a potential $10 million equity investment to support its goal of achieving positive cash flow by the end of 2025.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.